Healthy
Conditions
Brief summary
Study to assess the safety and tolerability of 100 mg of duloxetine BID compared to 40 mg of duloxetine BID or placebo for 7 days
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy female subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age ≥ 40 years * BMI ≥ 18.5 and ≤ 29.9 kg/m2
Exclusion criteria
* Any finding at any of the medical examinations (including blood pressure, pulse rate and ECG (electrocardiogram)) deviating from normal and of clinical relevance (resting heart rate greater than 100 bpm or tachyarrhythmia) * History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders (except thyroid hormones and hormonal replacement therapy) * History of relevant orthostatic hypotension, fainting spells and blackouts * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator, any bleeding disorder including prolonged or habitual bleeding, other hematologic disease, cerebral bleeding (e.g. after a car accident), commotio cerebri * Intake of drugs with a long half-life (\> 24 hours) within 1 month prior to administration * Use of any drugs that might influence the results of the trial (especially CYP2D6 or CYP1A2 modulating substances) within 2 weeks prior to administration or during the trial * Participation in another trial with an investigational drug within 2 months prior to administration or during trial * Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days * Alcohol abuse (\> 60 g/day) * Caffeine abuse (\> 4 cups/day) * Drug abuse * Blood donation within 1 month prior to administration or during the trial * Excessive physical activities within 10 days prior to administration or during the trial * Any laboratory value outside the clinically accepted reference range * Ineffective contraception
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of tolerability by investigator on a 4-point scale | Up to day 14 after drug administration | — |
| Number of subjects with adverse events | Up to day 14 after drug administration | — |
| Number of subjects with clinically relevant findings in electrocardiogram (ECG) | Up to day 14 after drug administration | — |
| Number of subjects with clinically relevant findings in vital signs | Up to day 14 after drug administration | systolic and diastolic blood pressure |
| Number of subjects with abnormal changes in laboratory parameters | Up to day 14 after drug administration | — |
Outcome results
None listed